STOCK TITAN

[SCHEDULE 13G/A] Beta Bionics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

This Schedule 13G/A discloses significant beneficial ownership positions in Beta Bionics common stock by Zone Healthcare, multiple Farallon-managed funds, their management company and numerous Farallon individual reporting persons. Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. are each reported with shared voting and dispositive power over 3,277,220 shares (7.6% of the class). Several Farallon funds disclose smaller direct holdings (examples include 166,877 and 380,597 shares). A set of Farallon individual reporting persons are each shown with an aggregate beneficial amount of 4,203,920 shares (9.7% of the class), and the filing states these individuals may be deemed beneficial owners based on their roles while disclaiming beneficial ownership.

The filing is submitted pursuant to the passive investor provision of the rules and includes a certification that the securities were not acquired to change or influence control. The Reporting Persons indicate they neither affirm nor disclaim the existence of a group among them and include standard power-of-attorney signatures for the reporting entities and individuals.

Questo Schedule 13G/A segnala posizioni significative di proprietà beneficiaria sulle azioni ordinarie di Beta Bionics da parte di Zone Healthcare, di più fondi gestiti da Farallon, della loro società di gestione e di numerose persone fisiche legate a Farallon. Zone Healthcare Holdings, LLC e Farallon Capital Management, L.L.C. risultano ciascuna titolari di poteri condivisi di voto e dispositivi su 3.277.220 azioni (7,6% della categoria). Diversi fondi Farallon dichiarano partecipazioni dirette più contenute (ad esempio 166.877 e 380.597 azioni). Un gruppo di persone fisiche di Farallon è indicato ciascuna con un ammontare beneficiario aggregato di 4.203.920 azioni (9,7% della categoria), e il documento specifica che tali individui possono essere considerati beneficiari sulla base dei loro ruoli, pur disconoscendo la titolarità beneficiaria.

La comunicazione è presentata ai sensi della disposizione per investitori passivi delle norme e contiene una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo. I soggetti dichiarante dichiarano di non affermare né negare l’esistenza di un gruppo tra loro e includono le consuete firme per procura per le entità e le persone che presentano la comunicazione.

Este Schedule 13G/A revela posiciones significativas de propiedad beneficiaria en las acciones ordinarias de Beta Bionics por parte de Zone Healthcare, varios fondos gestionados por Farallon, su sociedad gestora y numerosas personas físicas vinculadas a Farallon. Zone Healthcare Holdings, LLC y Farallon Capital Management, L.L.C. aparecen cada una con poder compartido de voto y disposición sobre 3.277.220 acciones (7,6% de la clase). Varios fondos de Farallon declaran participaciones directas menores (por ejemplo, 166.877 y 380.597 acciones). Un conjunto de personas físicas de Farallon figura cada una con un importe beneficiario agregado de 4.203.920 acciones (9,7% de la clase), y la presentación indica que esas personas pueden considerarse beneficiarios en función de sus funciones, aunque niegan la titularidad beneficiaria.

La declaración se presenta conforme a la disposición para inversores pasivos de las normas e incluye una certificación de que los valores no fueron adquiridos para cambiar o influir en el control. Las Personas Informantes indican que ni afirman ni niegan la existencia de un grupo entre ellas e incluyen las firmas estándar por poder para las entidades y las personas que informan.

이 Schedule 13G/A는 Zone Healthcare, 여러 Farallon 계열 펀드, 그들의 운용사 및 다수의 Farallon 개인 보고자가 Beta Bionics 보통주에 대해 보유한 중요한 실질적 소유지위를 공시합니다. Zone Healthcare Holdings, LLC 및 Farallon Capital Management, L.L.C.는 각각 공유된 의결권 및 처분권을 통해 3,277,220주(총주식의 7.6%)를 보유한 것으로 보고됩니다. 여러 Farallon 펀드는 보다 작은 직접 보유를 신고하고 있으며(예: 166,877주 및 380,597주), 일부 Farallon 개인 보고자는 각각 총합 4,203,920주(총주식의 9.7%)의 실질적 보유를 가지고 있는 것으로 표시되어 있고, 이들은 자신의 직무로 인해 실질적 소유자로 간주될 수 있으나 실질적 소유권을 부인한다고 명시하고 있습니다.

이 신고서는 규정상의 수동 투자자 조항에 따라 제출되었으며, 증권이 지배권 변경 또는 영향력을 행사할 목적으로 취득되지 않았다는 인증을 포함합니다. 보고인들은 자신들 사이에 그룹이 존재한다고도, 존재하지 않는다고도 단정하지 않으며, 보고 단체 및 개인에 대한 표준 위임장 서명이 포함되어 있습니다.

Ce Schedule 13G/A révèle des positions importantes de propriété bénéficiaire d’actions ordinaires de Beta Bionics détenues par Zone Healthcare, plusieurs fonds gérés par Farallon, leur société de gestion et de nombreuses personnes physiques affiliées à Farallon. Zone Healthcare Holdings, LLC et Farallon Capital Management, L.L.C. sont chacune déclarées comme disposant conjointement du pouvoir de vote et du pouvoir de disposition sur 3 277 220 actions (7,6 % de la catégorie). Plusieurs fonds Farallon déclarent des avoirs directs plus modestes (par exemple 166 877 et 380 597 actions). Un ensemble de personnes physiques de Farallon sont chacune indiquées avec un montant bénéficiaire agrégé de 4 203 920 actions (9,7 % de la catégorie), et le dépôt précise que ces individus peuvent être réputés bénéficiaires en raison de leurs fonctions, tout en déclinant la qualité de propriétaire bénéficiaire.

Le dépôt est soumis en vertu de la disposition relative aux investisseurs passifs et inclut une certification selon laquelle les titres n’ont pas été acquis dans le but de modifier ou d’influencer le contrôle. Les personnes déclarantes indiquent qu’elles n’affirment ni ne nient l’existence d’un groupe entre elles et incluent les signatures habituelles par procuration pour les entités et les personnes déclarantes.

Diese Schedule 13G/A offenbart wesentliche wirtschaftliche Beteiligungen an Stammaktien von Beta Bionics durch Zone Healthcare, mehrere von Farallon verwaltete Fonds, deren Managementgesellschaft und zahlreiche einzelne meldepflichtige Personen von Farallon. Zone Healthcare Holdings, LLC und Farallon Capital Management, L.L.C. werden jeweils mit gemeinsamem Stimm- und Verfügungsrecht über 3.277.220 Aktien (7,6% der Klasse) angegeben. Mehrere Farallon-Fonds melden kleinere Direkthaltungen (zum Beispiel 166.877 und 380.597 Aktien). Eine Reihe einzelner meldepflichtiger Personen von Farallon wird jeweils mit einem aggregierten wirtschaftlichen Anteil von 4.203.920 Aktien (9,7% der Klasse) aufgeführt, und die Einreichung stellt fest, dass diese Personen aufgrund ihrer Funktionen als wirtschaftliche Eigentümer angesehen werden könnten, während sie die wirtschaftliche Eigentümerschaft bestreiten.

Die Meldung wird gemäß der Regelung für passive Investoren eingereicht und enthält eine Bestätigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle zu verändern oder zu beeinflussen. Die meldenden Personen geben an, weder die Existenz einer Gruppe zu bejahen noch zu verneinen, und fügen die üblichen Vollmachtsunterschriften für die meldenden Einheiten und Personen bei.

Positive
  • Zone Healthcare and Farallon report shared voting/dispositive power over 3,277,220 shares (7.6% of class)
  • Farallon individual reporting persons are disclosed with an aggregate beneficial amount of 4,203,920 shares (9.7% of class)
  • Filing made under the passive investor rule (Section 13d-1(c)), with a certification that shares were not acquired to change or influence control
Negative
  • None.

Insights

TL;DR: Farallon-related entities report meaningful passive stakes—Zone/Farallon show 7.6% via ZHH LLC and individuals listed at 9.7% aggregate.

The Schedule 13G/A documents material passive positions in Beta Bionics by multiple Farallon-managed vehicles and affiliated individuals. The clear presentation of shared voting and dispositive power for 3,277,220 shares (7.6%) via Zone/Farallon entities and the listing of 4,203,920 shares (9.7%) under individual reporting persons are the most consequential data points for holders and observers. Filing under the passive investor rule signals no current intent to influence control, which limits immediate governance implications but identifies concentrated ownership that investors should monitor through subsequent filings.

TL;DR: Ownership concentrations are material but declared passive; governance impact is currently limited by disclaimers and the 13G filing route.

The disclosure shows multiple affiliated entities and senior managers connected to the same investment adviser structure, with reporting lines that could create de facto coordination despite legal disclaimers. The filing explicitly states the Reporting Persons "neither disclaim nor affirm the existence of a group," and individual managers are listed as having potential investment discretion. Because this is a Schedule 13G/A filed under the passive-investor provision, the stated posture is non-control; however, the aggregated percentages—especially the 9.7% figure noted for individual reporting persons—represent a meaningful ownership block from a governance perspective if holdings were to change or be recharacterized.

Questo Schedule 13G/A segnala posizioni significative di proprietà beneficiaria sulle azioni ordinarie di Beta Bionics da parte di Zone Healthcare, di più fondi gestiti da Farallon, della loro società di gestione e di numerose persone fisiche legate a Farallon. Zone Healthcare Holdings, LLC e Farallon Capital Management, L.L.C. risultano ciascuna titolari di poteri condivisi di voto e dispositivi su 3.277.220 azioni (7,6% della categoria). Diversi fondi Farallon dichiarano partecipazioni dirette più contenute (ad esempio 166.877 e 380.597 azioni). Un gruppo di persone fisiche di Farallon è indicato ciascuna con un ammontare beneficiario aggregato di 4.203.920 azioni (9,7% della categoria), e il documento specifica che tali individui possono essere considerati beneficiari sulla base dei loro ruoli, pur disconoscendo la titolarità beneficiaria.

La comunicazione è presentata ai sensi della disposizione per investitori passivi delle norme e contiene una certificazione che i titoli non sono stati acquisiti per modificare o influenzare il controllo. I soggetti dichiarante dichiarano di non affermare né negare l’esistenza di un gruppo tra loro e includono le consuete firme per procura per le entità e le persone che presentano la comunicazione.

Este Schedule 13G/A revela posiciones significativas de propiedad beneficiaria en las acciones ordinarias de Beta Bionics por parte de Zone Healthcare, varios fondos gestionados por Farallon, su sociedad gestora y numerosas personas físicas vinculadas a Farallon. Zone Healthcare Holdings, LLC y Farallon Capital Management, L.L.C. aparecen cada una con poder compartido de voto y disposición sobre 3.277.220 acciones (7,6% de la clase). Varios fondos de Farallon declaran participaciones directas menores (por ejemplo, 166.877 y 380.597 acciones). Un conjunto de personas físicas de Farallon figura cada una con un importe beneficiario agregado de 4.203.920 acciones (9,7% de la clase), y la presentación indica que esas personas pueden considerarse beneficiarios en función de sus funciones, aunque niegan la titularidad beneficiaria.

La declaración se presenta conforme a la disposición para inversores pasivos de las normas e incluye una certificación de que los valores no fueron adquiridos para cambiar o influir en el control. Las Personas Informantes indican que ni afirman ni niegan la existencia de un grupo entre ellas e incluyen las firmas estándar por poder para las entidades y las personas que informan.

이 Schedule 13G/A는 Zone Healthcare, 여러 Farallon 계열 펀드, 그들의 운용사 및 다수의 Farallon 개인 보고자가 Beta Bionics 보통주에 대해 보유한 중요한 실질적 소유지위를 공시합니다. Zone Healthcare Holdings, LLC 및 Farallon Capital Management, L.L.C.는 각각 공유된 의결권 및 처분권을 통해 3,277,220주(총주식의 7.6%)를 보유한 것으로 보고됩니다. 여러 Farallon 펀드는 보다 작은 직접 보유를 신고하고 있으며(예: 166,877주 및 380,597주), 일부 Farallon 개인 보고자는 각각 총합 4,203,920주(총주식의 9.7%)의 실질적 보유를 가지고 있는 것으로 표시되어 있고, 이들은 자신의 직무로 인해 실질적 소유자로 간주될 수 있으나 실질적 소유권을 부인한다고 명시하고 있습니다.

이 신고서는 규정상의 수동 투자자 조항에 따라 제출되었으며, 증권이 지배권 변경 또는 영향력을 행사할 목적으로 취득되지 않았다는 인증을 포함합니다. 보고인들은 자신들 사이에 그룹이 존재한다고도, 존재하지 않는다고도 단정하지 않으며, 보고 단체 및 개인에 대한 표준 위임장 서명이 포함되어 있습니다.

Ce Schedule 13G/A révèle des positions importantes de propriété bénéficiaire d’actions ordinaires de Beta Bionics détenues par Zone Healthcare, plusieurs fonds gérés par Farallon, leur société de gestion et de nombreuses personnes physiques affiliées à Farallon. Zone Healthcare Holdings, LLC et Farallon Capital Management, L.L.C. sont chacune déclarées comme disposant conjointement du pouvoir de vote et du pouvoir de disposition sur 3 277 220 actions (7,6 % de la catégorie). Plusieurs fonds Farallon déclarent des avoirs directs plus modestes (par exemple 166 877 et 380 597 actions). Un ensemble de personnes physiques de Farallon sont chacune indiquées avec un montant bénéficiaire agrégé de 4 203 920 actions (9,7 % de la catégorie), et le dépôt précise que ces individus peuvent être réputés bénéficiaires en raison de leurs fonctions, tout en déclinant la qualité de propriétaire bénéficiaire.

Le dépôt est soumis en vertu de la disposition relative aux investisseurs passifs et inclut une certification selon laquelle les titres n’ont pas été acquis dans le but de modifier ou d’influencer le contrôle. Les personnes déclarantes indiquent qu’elles n’affirment ni ne nient l’existence d’un groupe entre elles et incluent les signatures habituelles par procuration pour les entités et les personnes déclarantes.

Diese Schedule 13G/A offenbart wesentliche wirtschaftliche Beteiligungen an Stammaktien von Beta Bionics durch Zone Healthcare, mehrere von Farallon verwaltete Fonds, deren Managementgesellschaft und zahlreiche einzelne meldepflichtige Personen von Farallon. Zone Healthcare Holdings, LLC und Farallon Capital Management, L.L.C. werden jeweils mit gemeinsamem Stimm- und Verfügungsrecht über 3.277.220 Aktien (7,6% der Klasse) angegeben. Mehrere Farallon-Fonds melden kleinere Direkthaltungen (zum Beispiel 166.877 und 380.597 Aktien). Eine Reihe einzelner meldepflichtiger Personen von Farallon wird jeweils mit einem aggregierten wirtschaftlichen Anteil von 4.203.920 Aktien (9,7% der Klasse) aufgeführt, und die Einreichung stellt fest, dass diese Personen aufgrund ihrer Funktionen als wirtschaftliche Eigentümer angesehen werden könnten, während sie die wirtschaftliche Eigentümerschaft bestreiten.

Die Meldung wird gemäß der Regelung für passive Investoren eingereicht und enthält eine Bestätigung, dass die Wertpapiere nicht erworben wurden, um die Kontrolle zu verändern oder zu beeinflussen. Die meldenden Personen geben an, weder die Existenz einer Gruppe zu bejahen noch zu verneinen, und fügen die üblichen Vollmachtsunterschriften für die meldenden Einheiten und Personen bei.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Zone Healthcare Holdings, LLC
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its Manager
Date:08/13/2025
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/13/2025
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/13/2025
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/13/2025
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025

FAQ

Who filed the Schedule 13G/A for Beta Bionics (BBNX)?

The statement is filed by Zone Healthcare Holdings, LLC; multiple Farallon-managed funds and entities; Farallon Capital Management, L.L.C.; Farallon Partners, L.L.C.; related general partners; and named Farallon individual reporting persons.

How many shares does Zone Healthcare/Farallon report owning in Beta Bionics (BBNX)?

Zone Healthcare Holdings, LLC and related Farallon reporting entities are shown with shared voting and dispositive power over 3,277,220 shares, representing 7.6% of the class as reported on the cover pages.

What is the 4,203,920 shares figure listed in the filing for BBNX?

Several Farallon individual reporting persons are each listed with an aggregate beneficial amount of 4,203,920 shares, representing 9.7% of the class as shown on their respective cover pages.

Was this filing made as a passive investor under Schedule 13G?

Yes. The Reporting Persons state the Schedule is filed pursuant to the passive investor rule and include a certification that the securities were not acquired to change or influence control.

Do the Reporting Persons claim control or a group agreement in this filing for BBNX?

The filing states the Reporting Persons "neither disclaim nor affirm the existence of a group among them," and they assert the positions are not held to change or influence control.
Beta Bionics, Inc.

NASDAQ:BBNX

BBNX Rankings

BBNX Latest News

BBNX Latest SEC Filings

BBNX Stock Data

618.15M
41.59M
6.49%
98.18%
11.05%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE